Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06218914 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 18
- Study locations
NCT06218914: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer, sponsored by AstraZeneca.
NCT06218914 is a Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 108 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (83% lower). The trial reports 18 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06218914, a Phase 1 study of Non-Small Cell Lung Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 18
- Study locations
Study Summary
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
Primary Outcome
Incidence of DLTs, treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Conditions Studied
Interventions
- BIOLOGICAL NT-112: Autologous, engineered T Cells targeting KRAS G12D
- BIOLOGICAL AZD0240: Autologous, engineered T Cells targeting KRAS G12D
Study Locations (18)
California
- Research Site - Duarte
- Research Site - Los Angeles
- Research Site - Newport Beach
Texas
- Research Site - Dallas
- Research Site - Galveston
- Research Site - Houston
New York
- Research Site - New York
- Research Site - New York
Pennsylvania
- Research Site - Philadelphia
- Research Site - Pittsburgh
Florida
- Research Site - Jacksonville
Illinois
- Research Site - Chicago
Kansas
- Research Site - Westwood
Massachusetts
- Research Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2024-03-22 |
| Est. Completion | 2043-11-18 |
| Phase | Phase 1 |
What NCT06218914 shows while recruiting
NCT06218914 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (83% lower).
The record links to 6 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which NT-112: Autologous, engineered T Cells targeting KRAS G12D is the first listed.
NCT06218914 lists 18 locations in 12 states (California, Texas, New York).
Frequently Asked Questions
What is clinical trial NCT06218914 about?
NCT06218914 is a clinical study titled "Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors". Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
What is the current status of trial NCT06218914?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2024-03-22. Estimated completion is 2043-11-18.
What conditions does trial NCT06218914 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Endometrial Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Adult, Colorectal Carcinoma.
What interventions are being tested in trial NCT06218914?
The interventions under investigation include: NT-112: Autologous, engineered T Cells targeting KRAS G12D (BIOLOGICAL), AZD0240: Autologous, engineered T Cells targeting KRAS G12D (BIOLOGICAL).
Who is sponsoring clinical trial NCT06218914?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06218914 being conducted?
This trial has 18 study locations across California, Florida, Illinois, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06218914's enrollment target sits among peer trials
108 225th of 454 higher than 230 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI